Recurrent estrogen receptor α (ERα)-positive breast and ovarian cancers are often therapy resistant. Using screening and functional validation, we identified BHPI, a potent noncompetitive small molecule ERα biomodulator that selectively blocks proliferation of drug-resistant ERα-positive breast and ovarian cancer cells. In a mouse xenograft model of breast cancer, BHPI induced rapid and substantial tumor regression. Whereas BHPI potently inhibits nuclear estrogen-ERα-regulated gene expression, BHPI is effective because it elicits sustained ERα-dependent activation of the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR), and persistent inhibition of protein synthesis. BHPI distorts a newly described action of estrogen-ERα: mild and transient UPR activation. In contrast, BHPI elicits massive and sustained UPR activation, converting the UPR from protective to toxic. In ERα + cancer cells, BHPI rapidly hyperactivates plasma membrane PLCγ, generating inositol 1,4,5-triphosphate (IP 3 ), which opens EnR IP 3 R calcium channels, rapidly depleting EnR Ca 2+ stores. This leads to activation of all three arms of the UPR. Activation of the PERK arm stimulates phosphorylation of eukaryotic initiation factor 2α (eIF2α), resulting in rapid inhibition of protein synthesis. The cell attempts to restore EnR Ca 2+ levels, but the open EnR IP 3 R calcium channel leads to an ATP-depleting futile cycle, resulting in activation of the energy sensor AMP-activated protein kinase and phosphorylation of eukaryotic elongation factor 2 (eEF2). eEF2 phosphorylation inhibits protein synthesis at a second site. BHPI's novel mode of action, high potency, and effectiveness in therapyresistant tumor cells make it an exceptional candidate for further mechanistic and therapeutic exploration.
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estrogen receptor | drug discovery | breast cancer | unfolded protein response | ovarian cancer E strogens, acting via estrogen receptor α (ERα), stimulate tumor growth (1) (2) (3) . Approximately 70% of breast cancers are ERα-positive and most deaths due to breast cancer are in patients with ERα + tumors (2, 4) . Endocrine therapy using aromatase inhibitors to block estrogen production, or tamoxifen and other competitor antiestrogens, often results in selection and outgrowth of resistant tumors. Although 30-70% of epithelial ovarian tumors are ERα-positive (1), endocrine therapy is largely ineffective (5) (6) (7) . After several cycles of chemotherapy, tumors recur as resistant ovarian cancer (5) , and most patients die within 5 years (8) .
Noncompetitive ERα inhibitors targeting this unmet therapeutic need, including DIBA, TPBM, TPSF, and LRH-1 inhibitors that reduce ERα levels, show limited specificity, require high concentrations (>5 μM), and usually have not advanced through preclinical development (9) (10) (11) (12) . These noncompetitive ERα inhibitors and competitor antiestrogens are primarily cytostatic and act by preventing estrogen-ERα action; therefore, they are largely ineffective in therapy-resistant ERα containing cancer cells that no longer require estrogens and ERα for growth.
To target the estrogen-ERα axis in therapy-resistant cancer cells, we developed (13) and implemented an unbiased pathwaydirected screen of ∼150,000 small molecules. We identified ∼2,000 small molecule biomodulators of 17β-estradiol (E 2 )-ERα-induced gene expression, evaluated these biomodulators for inhibition of E 2 -ERα-induced cell proliferation, and performed simple follow-on assays to identify inhibitors with a novel mode of action. Here, we describe 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2H-indol-2-one (BHPI), our most promising small molecule ERα biomodulator.
In response to stress, cancer cells often activate the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). We recently showed that as an essential component of the E 2 -ERα proliferation program, estrogen induces a different mode of UPR activation, a weak anticipatory activation of the UPR before increased protein folding loads that accompany cell proliferation. This weak and transient E 2 -ERα-mediated UPR activation is protective (14) . BHPI distorts this normal action of E 2 -ERα and induces a massive and sustained ERα-dependent activation of the UPR, converting UPR activation from cytoprotective to cytotoxic. Moreover, independent of its effect on the UPR and protein synthesis, BHPI rapidly suppresses E 2 -ERα-regulated gene expression.
Results

BHPI Is Effective in Drug-Resistant ERα
+ Breast and Ovarian Cancer Cells.
We investigated BHPI's effect on proliferation in therapy-sensitive and therapy-resistant cancer cells. BHPI (SI Appendix, Fig. S1 A
Significance
Late-stage estrogen receptor α (ERα)-positive breast and ovarian cancers exhibit many regulatory alterations and therefore resist therapy. Our novel ERα inhibitor, BHPI, stops growth and often kills drug-resistant ERα + cancer cells and induces rapid and substantial tumor regression in a mouse model of human breast cancer. BHPI distorts a normally protective estrogen-ERα-mediated activation of the unfolded protein response (UPR) and elicits sustained UPR activation. The UPR cannot be deactivated because BHPI, acting at a second site, inhibits production of proteins that normally help turn it off. This persistent activation converts the UPR from protective to lethal. Targeting therapy-resistant ERα-positive cancer cells by converting the UPR from cytoprotective to cytotoxic may hold significant therapeutic promise.
and B) completely inhibited proliferation of ERα + breast ( Fig. 1 A and E-G), endometrial (Fig. 1C) , and ovarian ( Fig. 1 B, H, and I ) cancer cells, and had no effect in counterpart ERα − cell lines (Fig.  1D ). At 100-1,000 nM, BHPI completely blocked proliferation in diverse drug-resistant cell lines: 4-hydroxytamoxifen (4-OHT)-resistant ZR-75-1 breast cancer cells (Fig. 1E) ; tamoxifen and fulvestrant/ICI 182,780 (ICI)-resistant BT-474 cells (Fig. 1F) (15) ; epidermal growth factor (EGF)-stimulated T47D breast cancer cells, which are resistant to 4-OHT, ICI, and raloxifene (RAL) (Fig.  1G) ; Caov-3 ovarian cancer cells, which are resistant to 4-OHT, ICI, and cisplatin ( Fig. 1H) (16) ; and multidrug resistant OVCAR-3 ovarian cancer cells, which are resistant to 5 μM ICI (Fig. 1I) and to paclitaxel, cisplatin, and other anticancer drugs (17, 18) . BHPI blocked proliferation in all 15 ERα + cell lines and at 10 μM had no effect on proliferation in all 12 ERα − cell lines tested (SI Appendix, Fig. S2 ). Furthermore, BHPI blocked anchorage-independent growth of MCF-7 cells in soft agar (SI Appendix, Fig. S3 ).
BHPI Induces Tumor Regression. We next evaluated BHPI in a mouse xenograft model using MCF-7 cell tumors (19) . For each tumor, cross-sectional area at day 0 (∼45 mm 2 ) was set to 0%. Control (vehicle injected) and BHPI-treated mice were continuously exposed to estrogen. After daily i.p. injections for 10 d, the tumors in the vehicle-treated mice exhibited continued robust growth (Fig. 2, red bars) . Whereas BHPI at 1 mg/kg every other day was ineffective (SI Appendix, Fig. S4A ), initiation of 15 mg/kg daily BHPI treatment resulted in rapid regression of 48/52 tumors (Fig. 2 , blue bars). BHPI easily exceeded the goal of >60% tumor growth inhibition proposed as a benchmark more likely to lead to clinical response (20) . Furthermore, BHPI, at 10 mg/kg every other day, ultimately stopped tumor growth and final tumor weight was reduced ∼60% compared with controls (SI Appendix, Fig. S4 A and B) . BHPI was well tolerated; BHPI-treated and control mice exhibited similar food intake and weight gain (SI Appendix, Fig. S4 C and D Fig. S5 A and B) . BHPI does not inhibit protein synthesis in ERα-negative MCF-10A breast cells, but gains the ability to inhibit protein synthesis when ERα is stably expressed in isogenic MCF10A ER IN9 cells (Fig. 3B) (21) . Notably, BHPI loses the ability to inhibit protein synthesis when ERα in the stably transfected cells is knocked down with siRNA ( Fig. 3C and SI Appendix, Fig. S6A ) or is degraded by ICI (Fig. 3D) . Furthermore, increasing the ERα level in MCF7ERαHA cells (22) , stably transfected to express doxycycline-inducible ERα, progressively increased BHPI inhibition of protein synthesis (Fig.  3E ). BHPI does not work by activating the estrogen binding protein GPR30. BHPI has no effect on cell proliferation (SI Appendix, Inhibiting mechanistic target of rapamycin (mTOR) signaling did not strongly inhibit protein synthesis (SI Appendix, Fig. S6D ), suggesting BHPI is unlikely to work through mTOR. We next investigated whether initial inhibition of protein synthesis by BHPI is due to activation of the UPR. There are three UPR arms. The transmembrane kinase PERK is activated by autophosphorylation. p-PERK phosphorylates eukaryotic initiation factor 2α (eIF2α), inhibiting translation of most mRNAs (SI Appendix, Fig. S7A ) (24, 25) . The other arms of the UPR initiate with ATF6α activation (SI Appendix, Fig. S7B ), leading to increased protein folding capacity and activation of IRE1α, which alternatively splices XBP1, producing active spliced (sp)-XBP1 (SI Appendix, Fig. S7C ) (24, 25) . In ERα + MCF-7 and T47D cells, but not in ERα − MDA-MB-231 cells, BHPI rapidly inhibited protein synthesis (SI Appendix, and SI Appendix, Fig. S8 B and C) . Downstream readouts of eIF2α phosphorylation, CHOP and GADD34 mRNAs, were rapidly induced by BHPI (SI Appendix, Fig. S8 D and E) . Consistent with BHPI inhibiting protein synthesis through eIF2α-Ser51 phosphorylation, transfecting cells with a dominant-negative eIF2α-S51A mutant largely prevented BHPI from inhibiting protein synthesis (SI Appendix, Fig. S8F ). We next evaluated whether increases in eIF2α phosphorylation and rapid inhibition of protein synthesis occur through activation of PERK. p-PERK was increased 30 min after BHPI treatment ( Fig. 3F and SI Appendix, Fig. S8G ), and pretreating cells with a PERK inhibitor (PERKi) abolished rapid BHPI inhibition of protein synthesis (SI Appendix, Fig. S9A ). RNAi knockdown of PERK abolished BHPI inhibition of protein synthesis at 30 min and strongly inhibited BHPI-stimulated eIF2α phosphorylation ( Fig. 3G and SI Appendix, Fig. S9B ). Because PERK knockdown blocks rapid eIF2α phosphorylation, BHPI is not inhibiting translation by activating other upstream kinases that phosphorylate eIF2α. Furthermore, BHPI rapidly activates the ATF6α and IRE1α arms of the UPR, as shown by increased cleaved p50-ATF6α and sp-XBP1 (Fig. 3H ).
To explore how BHPI activates the UPR, we examined inhibition of protein synthesis by known UPR activators. Thapsigargin (THG) and ionomycin, which activate the UPR by release of Ca 2+ from the lumen of the EnR into the cytosol (24, 25), but not UPR activators that work by other mechanisms, elicited the rapid and near quantitative inhibition of protein synthesis seen with BHPI (SI Appendix, Fig. S10A ).
To test whether BHPI alters intracellular Ca
2+
, we monitored intracellular Ca 2+ with the calcium-sensitive dye Fluo-4 AM. In MCF-7 cells, BHPI produced a large and sustained increase in intracellular Ca 2+ in the presence of extracellular Ca 2+ and a large transient increase in intracellular Ca 2+ in the absence of extracellular calcium (Fig. 3I , Movie S1, and SI Appendix, Fig.  S10B ). Time-dependent changes in cytosol calcium in BHPItreated MCF-7 cells were quantitated (SI Appendix, Fig. S10B ). Because BHPI elicits a large increase in cytosol Ca 2+ when there is no extracellular Ca 2+ , BHPI is acting by depleting the Ca 2+ store in the EnR. BHPI had no effect on intracellular Ca 2+ in ERα − HeLa cells (SI Appendix, Fig. S10C ). We next identified the EnR Ca 2+ channel that opens after BHPI treatment. The inositol triphosphate receptor (IP 3 R) and ryanodine (RyR) receptors are the major EnR Ca 2+ channels. indicate a significant difference among groups (P < 0.05) using one-way ANOVA followed by Tukey's post hoc test. *P < 0.05, **P < 0.01. n.s., not significant. Treatment with 2-APB, which locks the IP 3 R Ca 2+ channels closed, but not closing the RyR Ca 2+ channels with high concentration ryanodine (Ry), abolished the rapid BHPI-ERα-mediated increase in cytosol Ca 2+ and inhibition of protein synthesis (Fig. 3 I and J) . Furthermore, RNAi knockdown of IP 3 R (SI Appendix, Fig. S11A) Fig. S11B ).
BHPI Strongly Activates Phospholipase C γ, Producing Inositol 1,4,5-Triphosphate. Inositol 1,4,5-triphosphate (IP 3 ) is produced when the activated phosphorylated plasma membrane enzyme, phospholipase C γ (PLCγ), hydrolyzes PIP 2 to diacylglycerol (DAG) and IP 3 . Supporting a role for PLCγ, siRNA knockdown of PLCγ (SI Appendix, Fig. S11C ) abolished the BHPI-mediated increase in cytosol Ca 2+ (SI Appendix, Fig. S11C ) and BHPI inhibition of protein synthesis (Fig. 3L) , and the PLCγ inhibitor U73122 abolished the BHPI-ERα increase in cytosol Ca 2+ (SI Appendix, Fig. S11C ). Confirming PLCγ's role, BHPI induces rapid PLCγ-Tyr 783 phosphorylation (SI Appendix, Fig. S11D ), and strongly increased IP 3 levels (Fig. 3M) . Supporting the idea that BHPI acts by distorting the newly described weak E 2 -ERα activation of the UPR (14) , BHPI induced a much larger increase in IP 3 levels than E 2 (Fig. 3M) .
Rapid BHPI activation of plasma membrane PLCγ indicates UPR activation is an extranuclear action of BHPI-ERα. PLCγ and ERα coimmunoprecipitate (27) , and overexpression of ERα in MCF7ERαHA cells further increased IP 3 levels in response to BHPI (SI Appendix, Fig. S11E ). Consistent with extranuclear ERα-dependent activation of the UPR, an estrogen-dendrimer conjugate (EDC) that cannot enter the nucleus (28), induced sp-XBP1, but not nuclear estrogen-regulated genes (SI Appendix, Fig.  S12) . A model depicting BHPI action is presented in Fig. 3N .
BHPI Inhibits E 2 -ERα-Regulated Gene Expression and Likely Interacts with ERα. Consistent with BHPI binding to E 2 -ERα, BHPI, but not an inactive close relative, compound 8 (SI Appendix, Fig.  S1B ), significantly altered the fluorescence emission spectrum of purified ERα (Fig. 4A) . We also tested whether BHPI alters the sensitivity of purified ERα ligand-binding domain (LBD) to protease digestion. Addition of BHPI followed by cleavage with proteinase K revealed a 15-kDa band in BHPI-treated ERα LBD that was nearly absent in the LBD treated with DMSO or compound 8 (Fig. 4B) .
Because BHPI interacts with ERα and distorts an extranuclear action of E 2 -ERα, we tested whether, independent of its ability to inhibit protein synthesis and activate the UPR, BHPI would also modulate nuclear E 2 -ERα-regulated gene expression. At early times when BHPI inhibited E 2 -ERα induction of pS2 mRNA, neither inhibiting protein synthesis with cycloheximide (CHX), nor activating the UPR with tunicamycin (TUN) or THG (SI Appendix, Fig. S13A ), inhibited induction of pS2 mRNA (Fig. 4C) . BHPI inhibited E 2 -ERα induction of pS2, GREB1, XBP1, CXCL2, and ERE-luciferase in ERα + MCF-7, and T47D cells (SI Appendix, Fig. S13 B-F) and blocked E 2 -ERα down-regulation of IL1-R1 and EFNA1 mRNA (SI Appendix, Fig. S13 E and G) . BHPI is not a competitive ERα inhibitor. Increasing the concentration of E 2 by 1,000-fold had no effect on BHPI inhibition of E 2 induction of pS2 mRNA (Fig. 4D) . Moreover, BHPI did not compete with E 2 for binding to ERα (SI Appendix, Fig. S14A ). Because BHPI inhibits E 2 -ERα induction and repression of gene expression, BHPI acts at the level of ERα and not by a general inhibition or activation of transcription.
BHPI did not alter ERα protein levels or nuclear localization (SI Appendix, Fig. S14 B and C) . Chromatin immunoprecipitation (ChIP) showed that BHPI strongly inhibited E 2 -stimulated recruitment of ERα and RNA polymerase II to the pS2 and GREB1 promoter regions (Fig. 4E and SI Appendix, Fig. S14D ). Consistent with BHPI inducing an ERα conformation exhibiting reduced affinity for gene regulatory regions, 10-fold overexpression of ERα in MCF7ERαHA cells abolished BHPI inhibition of induction of GREB1 mRNA (Fig. 4F) . BHPI still kills these cells because ERα overexpression enhances BHPI inhibition of protein synthesis (Fig. 3E) . Taken together, our data provide compelling evidence that BHPI is a new type of biomodulator, altering both nuclear and extranuclear actions of ERα. Fig. 3N ). This futile cycle rapidly depletes intracellular ATP, resulting in activation of AMP-activated protein kinase (AMPK) by AMPKα-Thr 172 phosphorylation (Fig. 5 A and B) . Moreover, the AMPK target, acetyl CoA-carboxylase (ACC) is rapidly phosphorylated (Fig. 5B) . Because thapsigargin, which depletes EnR Ca 2+ by inhibiting SERCA pumps, had no effect on ATP levels (Fig. 5A ) and did not increase levels of p-AMPKα and p-ACC (SI Appendix, Fig. S15A ), ATP depletion, rather than increased cytosol Ca 2+ , is responsible for AMPK activation. Importantly, preblocking SERCA pumps with thapsigargin abolished the BHPI-induced decline in ATP levels and phosphorylation of AMPKα (Fig. 5A) . 1 μM (B-F) ; C8, 500 nM (A) or 1 μM (B); CHX, 10 μM; THG, 1 μM; TUN, 10 μg/mL. Data are mean ± SEM (n = 3). **P < 0.01, ***P < 0.001, compared with +E 2 samples. n.s., not significant. factor 2, (eEF2) (Fig. 5C and SI Appendix, Fig. S15 B and C) . eEF2 phosphorylation is regulated by a single Ca 2+ /calmodulin-dependent kinase, eukaryotic elongation factor 2 kinase (CAMKIII/eEF2K). eEF2K is inhibited by mTORC1-p70 S6K and ERK-p90 RSK through eEF2K-Ser 366 phosphorylation and activated by Ca 2+ /calmodulin and AMPK (29, 30) . BHPI increases cytosol Ca 2+ and activates AMPK, but inhibiting AMPK did not inhibit eEF2 phosphorylation (SI Appendix, Fig. S15D ). BHPI also rapidly induces a transient increase in ERK1/2 activation (SI Appendix, Fig.  S15 E and F) , which stimulates ERK-p90 RSK and mTORC1-p70 S6K activation (31) . Together, these pathways induce eEF2K-Ser 366 phosphorylation (Fig. 5D ) and prevent increases in peEF2 for ∼1 h after BHPI treatment ( Fig. 5C and SI Appendix, Fig. S15G ). Consistent with this mechanism, blocking ERK activation with U0126 prevented BHPI from producing transient declines in eEF2 phosphorylation through inactivation of eEF2K (SI Appendix, Fig. S15G ).
UPR activation with conventional UPR activators produces transient eIF2α phosphorylation and inhibition of protein synthesis (SI Appendix, Figs. S15A and S16 A and B) in part because they induce BiP and p58 IPK chaperones (SI Appendix, Fig. S16 C  and D) . The chaperones help resolve UPR stress and inactivate the UPR. In contrast, BHPI blocks induction and reduces levels of BiP and p58 IPK protein (Fig. 5E ), leading to sustained eIF2α phosphorylation and inhibition of protein synthesis (SI Appendix, Figs. S5 and S8B). BHPI failed to increase p58 protein despite inducing p58 mRNA (Fig. 5E ), and at later times PERK inhibition failed to prevent BHPI from inhibiting protein synthesis (SI Appendix, Fig. S9A ). This is consistent with BHPI targeting protein synthesis at a second site at later times. Discussion BHPI and estrogen share the same ERα-dependent pathway for UPR activation: activation of PLCγ producing IP 3 , opening of the IP 3 R Ca 2+ channels, release of EnR Ca 2+ , and activation of the PERK, IRE1α, and ATF6α arms of the UPR (model in Fig.  3N ). We recently reported that as an early component of the proliferation program, E 2 -ERα weakly and transiently activates the UPR. We showed that E 2 -ERα elicits a mild and transient activation of the PERK arm of the UPR, while simultaneously increasing chaperone levels and protein folding capacity by activating the IRE1α and ATF6α arms of the UPR (14) . BHPI distorts this normal action of E 2 -ERα by increasing the amplitude and duration of UPR activation. Compared with E 2 , BHPI hyperactivates PLCγ, producing much higher IP 3 levels, Ca 2+ release from the EnR, and UPR activation. BHPI initially inhibits protein synthesis by strongly activating the PERK arm of the UPR. Knockdown of ERα, PLCγ, IP 3 R, and PERK blocked rapid BHPI inhibition of protein synthesis. Whereas BHPI activates the IRE1α and ATF6α UPR arms, by acting at later times to inhibit protein synthesis at a second site, BHPI prevents the synthesis of chaperones required to inactivate the UPR. Because the cell attempts to restore EnR Ca 2+ while the IP 3 R Ca 2+ channels remain open, BHPI rapidly depletes ATP (Fig. 3N) , resulting in activation of AMPK. Several actions of BHPI, including strong elevation of intracellular calcium, sustained UPR activation, long-term inhibition of protein synthesis, ATP depletion, and AMPK activation can potentially contribute to BHPI's ability to block cell proliferation. How the cascade of events initiated by BHPI enables BHPI to block cell proliferation, and often kill, ERα + cancer cells requires further exploration. Supporting BHPI targeting PLCγ and the UPR through ERα, independent of its effects on the UPR, BHPI inhibits E 2 -ERα-mediated induction and repression of gene expression.
BHPI and E 2 activation of plasma membrane-bound PLCγ, resulting in increased IP 3 , is an extranuclear action of ERα. Increasing the level of ERα increased IP 3 levels. Consistent with ERα and PLCγ interaction, they coimmunoprecipitate (27) . BHPI and E 2 induce Ca 2+ release in 1 min, too rapidly for action by regulating nuclear gene expression (14) . Furthermore, a membrane-impermeable estrogen-dendrimer induces the UPR marker sp-XBP1, but not nuclear E 2 -ERα-regulated genes.
The UPR plays important roles in tumorigenesis, therapy resistance, and cancer progression (14, 32) . Moderate and transient UPR activation by E 2 and other activators promotes an adaptive stress response, which increases UPR expression and confers protection from subsequent exposure to higher levels of cell stress (14, 33) . In contrast, sustained UPR activation triggers cell death. Because most current anticancer drugs inhibit a pathway or protein important for tumor growth or metastases, most UPR targeting efforts focus on inactivating a protective stress response by inhibiting UPR components (34) . UPR overexpression in cancer is associated with a poor prognosis (14) , suggesting that sustained lethal hyperactivation of the UPR by BHPI represents a novel alternative anticancer strategy.
BHPI can selectively target cancer cells, because its targets, ERα and the UPR, are both overexpressed in breast and ovarian cancers (14, 22, 32, 35) . Cells expressing low levels of ERα, more typical of nontransformed ERα-containing cells, such as PC-3 prostate cancer cells, were less sensitive to BHPI inhibition of protein synthesis (SI Appendix, Fig. S5 ), whereas doxycyclinetreated MCF7ERαHA cells expressing very high levels of ERα exhibited near complete inhibition of protein synthesis (Fig. 3E) . Consistent with low toxicity, in the xenograft study, BHPI-treated mice showed no evidence of gross toxicity. Most gynecological cancers show little dependence on estrogens for growth, and other noncompetitive ERα inhibitors have not demonstrated effectiveness in these cells. BHPI is highly effective in several breast and ovarian cancer drug-resistance models and extends the reach of ERα biomodulators to gynecologic cancers that do not respond to current endocrine therapies. BHPI's effectiveness in ERα-containing breast, ovarian, and endometrial cancer cells is consistent with the finding that female reproductive cancers exhibit common genetic alterations and might respond to the same drugs (36) and with our finding that E 2 -ERα weakly activates the UPR in breast and ovarian cancer cells (14) .
With its submicromolar potency, effectiveness in a broad range of therapy-resistant cancer cells, ability to induce substantial tumor regression, and unique mode of action, BHPI is a promising small molecule for therapeutic evaluation and mechanistic studies.
Materials and Methods
Additional methods are in SI Appendix, SI Materials and Methods.
Cell Culture and Reagents, Chemical Libraries, Screening, IP 3 Assays, Luciferase Assays, qRT-PCR, ChIP, Transfections, and in Vitro Binding Assays. Techniques are further described in SI Appendix, SI Materials and Methods.
Calcium Imaging. Cytoplasmic Ca 2+ concentrations were measured using the calcium-sensitive dye, Fluo-4 AM (SI Appendix, SI Materials and Methods).
Protein Synthesis. Protein synthesis rates were evaluated by measuring incorporation of 35 S-methionine into newly synthesized protein (SI Appendix,
SI Materials and Methods).
Mouse Xenograft. All experiments were approved by the Institutional Animal Care Committee of the University of Illinois at Urbana-Champaign. The MCF-7 cell mouse xenograft model has been described previously (19) , and studies were performed as described in SI Appendix, SI Materials and Methods.
Statistical Analysis. Calcium measurements are reported as mean ± SE. All other pooled measurements are represented as mean ± SEM. Two-tailed Student t tests or one-way ANOVA with post hoc Fisher's least significant difference tests were used for statistical significance (P < 0.05).
